PTC Therapeutics.
pharmaceutical company
- Reports this week
- 0
- Active events
- 1
- Connections
- 72
What's happening
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
PTC Therapeutics and PDS Biotechnology Corporation are competing in the biopharmaceutical sector.Some support1 report
-
Thrivent Financial for Lutherans bought a new position in PTC Therapeutics stock, while an insider sold shares of the company.Some support1 report
-
PTC Therapeutics achieved successful drug approval from the FDA and recorded its first commercial sales.Some support1 report
-
Bank of America adjusted its price target and rating for PTC Therapeutics.Some support1 report
-
The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.Some support2 reports2 developments inside
-
Truist Securities initiated coverage with a Buy rating on PTC Therapeutics, reviewing its pipeline for various genetic diseases.Speculative1 report
-
PTC Therapeutics seeks FDA approval for Sephience™, backed by positive Phase 2 results in Huntington's Disease, and plans a global launch in Europe.Some support3 reports1 development inside
-
FDA approved Sephience for PKU treatment, with ongoing review applications in Japan and Brazil.Some support2 reports
-
PTC Therapeutics outperformed the S&P 500 this year, according to data from August 8, 2025.Some support1 report
-
FDA issued a Complete Response Letter to PTC Therapeutics regarding vatiquinone for Friedreich's ataxia.Some support1 report
-
The FDA stated that efficacy was not demonstrated for PTC Therapeutics, prompting research notes from RBC Capital.Some support2 reports
-
PTC Therapeutics executives are scheduled to speak at the Cantor, Wells Fargo, and Morgan Stanley healthcare conferences in August 2025.Some support1 report
-
PTC Therapeutics' drug was approved and commercialized in Europe, with CEO Matthew Klein presenting on the commercial opportunity.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around PTC Therapeutics this week
News at the entities that move PTC Therapeutics most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves PTC Therapeutics
-
Cantor Fitzgerald OperationalThe event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.Moves PTC Therapeutics
-
SEC StructuralCNBC reports on FED rate decisions and their impact on the Main Street economy and SEC yields.Moves PTC Therapeutics
-
Royal Bank of Canada TransactionalRoyal Bank of Canada dropped its price objective for Crown Castle Inc., while Citigroup reiterated an outperform rating.Moves PTC Therapeutics
-
Morgan Stanley Mentioned togetherBank of America and Morgan Stanley are restricting third-party AI agents amid cybersecurity scares and a declared bank run threat.Moves PTC Therapeutics
-
MarketBeat Mentioned togetherMarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Moves PTC Therapeutics
Connections
The 15 strongest of 72, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA regulates PTC Therapeutics' drug development, requiring approval or rejection of its applications.
-
SEC Structural
PTC Therapeutics is subject to formal regulatory oversight and filing requirements by the SEC.
-
Matthew Klein Shared context
Matthew Klein serves as the CEO of PTC Therapeutics, making executive decisions and financial transactions.
-
Eric Pauwels Structural
Eric Pauwels holds the executive role of CBO at PTC Therapeutics.
-
Royal Bank of Canada Transactional
Royal Bank of Canada issues investment research reports and changes target prices for PTC Therapeutics.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides financial analysis and rating coverage for PTC Therapeutics.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald provides market commentary and research reports that influence PTC Therapeutics' market valuation.
-
Morgan Stanley Mentioned together
Morgan Stanley has issued and reaffirmed an overweight rating and price objective for PTC Therapeutics.
Show all 15 connections
-
Raymond James Financial Mentioned together
Raymond James Financial initiated stock coverage on PTC Therapeutics.
-
Thrivent Financial for Lutherans Transactional
Thrivent Financial bought a new position in PTC Therapeutics stock.
-
MarketBeat Mentioned together
MarketBeat provides analyst recommendations and ratings for PTC Therapeutics.
-
Citigroup Mentioned together
PTC Therapeutics receives financial research reports and rating upgrades from the market ecosystem.
-
TD Cowen Transactional
TD Cowen raised the rating and increased the target price for PTC Therapeutics.
-
China Transactional
The relationship was defined by a sale that was disclosed in a filing with the SEC.
-
Bank of America Mentioned together
No evidence found linking Bank of America and PTC Therapeutics in the provided timeline.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
1 eventShow 2 earlier months
July 2026
1 eventJune 2026
13 events- Morgan Stanley and Jefferies Financial Group raised their ratings and price objectives for PTC Therapeutics.
- Thrivent Financial for Lutherans bought a new position in PTC Therapeutics stock, while an insider sold shares of the company.
- PTC Therapeutics achieved successful drug approval from the FDA and recorded its first commercial sales.
- Bank of America adjusted its price target and rating for PTC Therapeutics.
- The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.
- Truist Securities initiated coverage with a Buy rating on PTC Therapeutics, reviewing its pipeline for various genetic diseases.
- PTC Therapeutics seeks FDA approval for Sephience™, backed by positive Phase 2 results in Huntington's Disease, and plans a global launch in Europe.
- FDA approved Sephience for PKU treatment, with ongoing review applications in Japan and Brazil.
- PTC Therapeutics outperformed the S&P 500 this year, according to data from August 8, 2025.
- FDA issued a Complete Response Letter to PTC Therapeutics regarding vatiquinone for Friedreich's ataxia.
- The FDA stated that efficacy was not demonstrated for PTC Therapeutics, prompting research notes from RBC Capital.
- PTC Therapeutics executives are scheduled to speak at the Cantor, Wells Fargo, and Morgan Stanley healthcare conferences in August 2025.
- PTC Therapeutics' drug was approved and commercialized in Europe, with CEO Matthew Klein presenting on the commercial opportunity.